about
1alpha,25-dihydroxyvitamin D3 inhibits matrix metalloproteinases induced by Mycobacterium tuberculosis infectionThe progress of angiogenic factors in the development of leukemiasLost in translation: animal models and clinical trials in cancer treatmentToxin-based therapeutic approachesBiological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis.Insights from Selective Non-phosphinic Inhibitors of MMP-12 Tailored to Fit with an S1' Loop Canonical ConformationThe discovery of MMP7 inhibitors exploiting a novel selectivity triggerSimple Pseudo-dipeptides with a P2' Glutamate: A NOVEL INHIBITOR FAMILY OF MATRIX METALLOPROTEASES AND OTHER METZINCINSA human laterality disorder caused by a homozygous deleterious mutation in MMP21Cross-talk between vascular endothelial growth factor and matrix metalloproteinases in the induction of neovascularization in vivoSuppressive effect of secretory phospholipase A2 inhibitory peptide on interleukin-1beta-induced matrix metalloproteinase production in rheumatoid synovial fibroblasts, and its antiarthritic activity in hTNFtg mice.Mmp-9, a potential target for cerebral ischemic treatment.Injectable and bioresponsive hydrogels for on-demand matrix metalloproteinase inhibitionEffects of novel semiselective matrix metalloproteinase inhibitors on ex vivo cardiac structure-function.MMPs initiate Schwann cell-mediated MBP degradation and mechanical nociception after nerve damage.Matrix metalloproteinase inhibitor batimastat alleviates pathology and improves skeletal muscle function in dystrophin-deficient mdx mice.Effect of the oral application of a highly selective MMP-13 inhibitor in three different animal models of rheumatoid arthritis.Tumor necrosis factor-alpha augments matrix metalloproteinase-9 production in skeletal muscle cells through the activation of transforming growth factor-beta-activated kinase 1 (TAK1)-dependent signaling pathwayDiscovery of novel inhibitors of a disintegrin and metalloprotease 17 (ADAM17) using glycosylated and non-glycosylated substrates.Pericellular proteolysis in cancerProteases in cardiometabolic diseases: Pathophysiology, molecular mechanisms and clinical applicationsAnalysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin SCharacterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro.The Ras antagonist, farnesylthiosalicylic acid (FTS), decreases fibrosis and improves muscle strength in dy/dy mouse model of muscular dystrophy.Expression of matrix metalloproteinases and their inhibitors in different immunohistochemical-based molecular subtypes of breast cancerFRET-based and other fluorescent proteinase probes.Development of a 'mouse and human cross-reactive' affinity-matured exosite inhibitory human antibody specific to TACE (ADAM17) for cancer immunotherapy.Using fluorogenic peptide substrates to assay matrix metalloproteinases.Stromal matrix metalloproteinase 2 regulates collagen expression and promotes the outgrowth of experimental metastases.Osteopontin-stimulated expression of matrix metalloproteinase-9 causes cardiomyopathy in the mdx model of Duchenne muscular dystrophyThe ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?Exosite interactions impact matrix metalloproteinase collagen specificities.Cathepsin L targeting in cancer treatment.Sustained Small Molecule Delivery from Injectable Hyaluronic Acid Hydrogels through Host-Guest Mediated RetentionSelective Inhibition of Membrane Type 1 Matrix Metalloproteinase Abrogates Progression of Experimental Inflammatory Arthritis: Synergy With Tumor Necrosis Factor BlockadeMatrix metalloproteases and PAR1 activation.Synthesis of Fmoc-Gly-Ile Phosphinic Pseudodipeptide: Residue Specific Conditions for Construction of Matrix Metalloproteinase Inhibitor Building BlocksMMPs as therapeutic targets--still a viable option?Targeting MMPs in acute and chronic neurological conditions.Matrix Metalloproteinases as Mediators of Primary and Secondary Cataracts
P2860
Q24648943-7BF8FF30-D8CB-4018-ADCA-9D4818E6E8C1Q26753835-A8A7B87B-F901-4839-98AE-E5B8C9A54137Q27000792-FA5B88A9-48A6-448F-AA14-537F27834098Q27013664-FAF83136-CFF7-417E-AE68-6FEE03257F10Q27311085-789389DB-710C-4004-9FBF-89D37D11391AQ27664274-A2F7DDFB-FE1E-4DE6-9704-F025C863E5EDQ27667564-80BD779C-1A9C-43A4-BDFD-A15A9A564463Q27681108-1BAE2569-F3DA-4FC7-877B-438F042E0F83Q28118429-49F3C577-87B3-4597-9266-D376B12476FCQ28576485-C317807A-4871-46C0-9410-59C87BF633F4Q33504871-C79B3583-D119-4005-BC1C-737DEF3BCBC3Q33612510-4AA167F0-92CB-4ADC-810E-7D86FDF308C3Q33650887-89277ABC-FE70-4FBC-BADD-D381D484FA5BQ33715912-D4411274-7DCD-463F-B69F-A311460A3A6DQ33834828-458428D0-AABE-4834-8931-EB2DDCE8E0F5Q33947243-00E8901C-1311-4A8F-BDE3-D4D2657C41FCQ34077691-52707F7F-99A5-42B8-A469-FE2B086B7E80Q34132341-FDAECF29-5226-47A8-9A6B-CED7C0CFBCA6Q34395100-0C5BCDAF-AB4C-4E12-B847-DED6866945ECQ34430691-9935C709-7775-46D2-9214-A6A91CC8FD4DQ34476390-C162D395-8508-4917-B927-53D85DA7279FQ34599128-6783CC9F-D824-431D-8D31-F72DF306D06AQ34631606-4E01BBB3-C10E-4093-B7DE-6D7841D92A44Q34708324-E7A548D1-5941-4255-A57D-FE9642422A5AQ34995520-474E8649-BB49-439D-84D1-58A7679553CEQ35086168-B4EB7699-A8A7-49E9-9B2E-5ACA418FE523Q35158112-832A9266-8DF7-4A49-9277-CE33A094426AQ35162671-8F104277-4E11-4A73-89FC-3917D4404CE8Q35171178-F8BDBFF5-F8D8-4D41-9EB6-F0AB44AB1AD3Q35175749-30363D8C-CB60-4D80-B5E2-82BA4F697EA7Q35206311-531AF5C6-3FF9-4FD0-98D5-587257C928B4Q35423858-7E799C0F-6009-4E11-82BE-DF8C26616E98Q36218199-1D1C4F23-453A-4BAA-A297-09643A0408DFQ36362400-69A3D31C-3E95-499A-90BA-816EEAE5786DQ36536688-47FF5B91-7C8C-4C3A-9008-F641B299A4D1Q36542806-58F5C17C-A51D-4195-9857-A5DB0410C270Q36587992-01FF48E1-B46F-446E-8BD6-EDF266ED71B4Q36908023-52DADC7D-E651-43B5-844E-07813E12B0E1Q36963155-DAFA461B-A382-4DB2-AEC0-56A5FB3CDC53Q36974860-BD9A3778-CEBA-4C5B-AED8-B62AFF24DCEB
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Matrix metalloproteinases as valid clinical targets.
@ast
Matrix metalloproteinases as valid clinical targets.
@en
type
label
Matrix metalloproteinases as valid clinical targets.
@ast
Matrix metalloproteinases as valid clinical targets.
@en
prefLabel
Matrix metalloproteinases as valid clinical targets.
@ast
Matrix metalloproteinases as valid clinical targets.
@en
P1476
Matrix metalloproteinases as valid clinical targets.
@en
P304
P356
10.2174/138161207779313551
P577
2007-01-01T00:00:00Z